AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16255877
Drug: anti-CD(4), CD(8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD(4), CD(8) monoclonal antibodies combined with cyclosporine A
Trial: 10354213
Drug: Hyperglycaemia (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (12 mmol L‐1)
Trial: 10354213
Drug: Euglycaemia (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (4 mmol L‐1)
Trial: 7867053
Drug: 1% chlorhexidine-fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine-fluoride gel (GCHXF)
Trial: 17917503
Drug: Darusentan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan (300 mg)
Trial: 1789394
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (low dose)
Trial: 7056273
Drug: Tolmesoxide (300‐900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolmesoxide (300‐900mg daily)
Trial: 27764682
Drug: Milk containing
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk containing 2.5ppm fluoride daily (T1)
Trial: 27764682
Drug: Milk containing
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk containing 5.0ppm fluoride daily (T3)
Trial: 27764682
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (T5)
Trial: 20180429
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C tablets plus intramuscular chymotrypsin (Control)
Trial: 11471263
Drug: Rectal thermometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal thermometry
Trial: 6118964
Drug: Prazosin 0.5
RxNorm normalized name: prazosin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 0.5 mg
Trial: 6118964
Drug: Salbutamol 1
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 1 mg
Trial: 24107738
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg, increased to 50 mg if needed after 4 weeks)
Trial: 15103544
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin beta (NeoRecormon) to maintain target Hb levels of 13‐15 g/dl
Trial: 15103544
Drug: Current practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current practice (no epoetin therapy until Hb levels decline below 10.5 g/dl)
Trial: 15103544
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin beta (NeoRecormon)
Trial: 11328423
Drug: Clomiphene citrate,
RxNorm normalized name: ClomiPHENE Citrate, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate, 50 mg/day, orally
Trial: 7992099
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside and IFN-alpha
Trial: 16813178
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of heloperidol
Trial: 10740947
Drug: Treatment designed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment designed to reduce risk of relapse
Trial: 1533504
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators (salbutamol and ipratropium bromide)
Trial: 31576916
Drug: Low- to
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low- to moderate-intensity aerobic exercise plus standard medical treatment
Trial: 31576916
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment without exercise intervention
Trial: 24602005
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral bolus dose of 6,8,10,3',5'‐(13)C5‐C3G
Trial: 22677568
Drug: Acacia fiber,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia fiber, psyllium fiber, and fructose (AFPFF) 16.8 g daily
Trial: 22677568
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 3350 with electrolytes (PEG+E) 0.5 g/kg daily
Trial: 17964516
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg every 6 hours for 5 doses)
Trial: 12196491
Drug: Complete liquid
RxNorm normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete liquid nutrition supplement containing energy, vitamins, and minerals, including enhanced levels of antioxidants
Trial: 12196491
Drug: Complete liquid
RxNorm normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete liquid nutrition supplement
Trial: 12196491
Drug: Complete liquid
RxNorm normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete liquid nutrition supplement and Noncaloric placebo drink
Trial: 7778530
Drug: Delapril 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 7.5 mg twice daily, increased to 15 mg twice daily after 2 weeks
Trial: 7778530
Drug: Enalapril 2.5
RxNorm normalized name: enalapril 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5 mg twice daily, increased to 5 mg twice daily after 2 weeks
Trial: 6938020
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Stilboestrol
Trial: 31722536
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy plus guideline-directed medical therapy
Trial: 10367415
Drug: Radical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical treatment of localized disease
Trial: 8006249
Drug: Angina-guided plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angina-guided plus ambulatory ECG ischemia-guided medical therapy
Trial: 1234491
Drug: Cyclizine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine (50 mg)
Trial: 1234491
Drug: Perphenazine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (5 mg)
Trial: 1234491
Drug: Perphenazine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (2.5 mg)
Trial: 23581458
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation of V. cinerea for 3 months
Trial: 23581458
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation of V. cinerea
Trial: 21812735
Drug: Desvenlafaxine 200
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 200 to 400 mg/d
Trial: 19804822
Drug: Co-therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-therapy with topiramate (TPR)
Trial: 16434675
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate therapy
Trial: 9185645
Drug: Arbutamine infusion
RxNorm normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arbutamine infusion with technetium-99m sestamibi
Trial: 9185645
Drug: Arbutamine infusion
RxNorm normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arbutamine infusion with echocardiography
Trial: 3534315
Drug: Fluoxymesterone for
RxNorm normalized name: Fluoxymesterone
DrugBank: Fluoxymesterone (DB01185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone for 3 days before and on the day of chemotherapy
Trial: 3534315
Drug: Cyclic intravenous
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic intravenous chemotherapy with aminoglutethimide and hydrocortisone
Trial: 22015818
Drug: teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriparatide 20 μg/d
Trial: 22015818
Drug: alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alendronate 10 mg/d
Trial: 20549236
Drug: Artesunate (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (standard dosage schedule)
Trial: 12858617
Drug: 24-week theory-based
RxNorm normalized name: Sel-24 free base
DrugBank: SEL-24 (DB18082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week theory-based physical activity program (treatment group, n = 29)
Trial: 27006452
Drug: Self‐guided therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐guided therapy
Trial: 24977347
Drug: Agomelatine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 400 mg
Trial: 22162481
Drug: 0.2 mg/kg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Trial: 22162481
Drug: 0.5 mg/kg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/wk LB03002 for 36 months (n=13)
Trial: 22162481
Drug: 0.7 mg/kg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Trial: 22162481
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH 0.03 mg/kg/d for 24 months, switched to 0.5 mg/kg/wk LB03002 for 12 months (n=12)
Trial: 20412107
Drug: Oral D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-penicillamine (DPA) at 100 mg/kg/dose every 8 hours for 3 days, followed by 50 mg/kg/day for 11 days
Trial: 20412107
Drug: Oral D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-penicillamine (DPA)
Trial: 9063959
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 1 week before surgery
Trial: 1715297
Drug: cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream base only
Trial: 30477961
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg/day for 2 weeks
Trial: 30477961
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg/day for 4 weeks
Trial: 17888856
Drug: CBT+NRT (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT+NRT (nicotine replacement therapy)
Trial: 10737427
Drug: SQV‐SGC 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV‐SGC 1200 mg, NFV 750 mg, SQV‐SGC 800 mg plus NFV 750 mg, all with two NRTIs, and SQV‐SGC 800 mg plus NFV 750 mg alone, all three times daily for 48 weeks
Trial: 10737427
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (SQV‐SGC and NFV)
Trial: 10737427
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with either single protease inhibitor
Trial: 8933488
Drug: 14% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% CHO solution (HCHO)
Trial: 8933488
Drug: 7% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% CHO solution (NCHO)
Trial: 8933488
Drug: 4.2% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2% CHO solution (LCHO)
Trial: 1425883
Drug: Bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 400 mg/day (slow release formulation)
Trial: 29461392
Drug: 500‐mL colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mL colloid preload followed by 500‐mL crystalloid coload
Trial: 29461392
Drug: 1000‐mL crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000‐mL crystalloid coload
Trial: 27893820
Drug: Placebo 500
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg once daily for three days
Trial: 12209673
Drug: Pemetrexed/gemcitabine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed/gemcitabine combination
Trial: 10617249
Drug: Continuous 1
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 1 mg E2
Trial: 10617249
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2/30 microg NGM
Trial: 10617249
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2/90 microg NGM
Trial: 10617249
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2/180 microg NGM
Trial: 7856897
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg.kg‐1 followed by 1 mg.kg‐1.h‐1)
Trial: 7856897
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (doses < 10 mg.kg‐1)
Trial: 7856897
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (all doses)
Trial: 2023868
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment (3.0 MHz, 1.0 W/cm2 for 5 min)
Trial: 2023868
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (massage with gels without ultrasound for 5 min)
Trial: 31355692
Drug: Usual occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual occupational therapy (Control)
Trial: 25545380
Drug: ZOL (zoledronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOL (zoledronic acid) 5 mg annually for 9 years (Z9)
Trial: 25545380
Drug: Placebo (Z6P3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Z6P3) after 6 years of ZOL treatment
Trial: 20061311
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (CC + PST)
Trial: 16270636
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (certoparin 3000 anti Xa IU) subcutaneously once-daily
Trial: 16270636
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5000 IU) subcutaneously three-times daily
Trial: 16270636
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (certoparin)
Trial: 7601298
Drug: Thymomodulin treatment
RxNorm normalized name: thymomodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymomodulin treatment
Trial: 394268
Drug: lidamidine hydrochloride
RxNorm normalized name: lidamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidamidine hydrochloride (10 mg)
Trial: 394268
Drug: lidamidine hydrochloride
RxNorm normalized name: lidamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidamidine hydrochloride (18 mg)
Trial: 31320504
Drug: Music medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music medicine (noise-canceling headphone-delivered)
Trial: 31320504
Drug: Midazolam (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1-2 mg intravenous)
Trial: 23289819
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg for 10 days
Trial: 16766412
Drug: 24-hour nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour nicotine patch
Trial: 16766412
Drug: 16-hour nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-hour nicotine patch
Trial: 15534490
Drug: Subcutaneous CPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous CPG 7909 injection
Trial: 15534490
Drug: Subcutaneous CPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous CPG 7909 injection (second dose)
Trial: 15534490
Drug: Intravenous CPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CPG 7909 injection
Trial: 11251475
Drug: Bicarbonate solution
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate solution
Trial: 11251475
Drug: Lactate solution
RxNorm normalized name: lactate Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate solution
Trial: 8296180
Drug: Regular deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular deep relaxation training (15 min sessions, daily for 6 months)
Trial: 29551350
Drug: Eberconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eberconazole 1% otic solution
Trial: 18793575
Drug: Avosentan 50
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avosentan 50 mg after a high-fat, high-calorie breakfast
Trial: 18793575
Drug: Avosentan 50
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avosentan 50 mg administered in the fasted state
Trial: 2352762
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) with naloxone (50 mg)
Trial: 103114
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of haloperidol and low dose piribedil
Trial: 28392165
Drug: sorafenib or
RxNorm normalized name: sorafenib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib or sunitinib (targeted therapy)
Trial: 19541299
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue treatment for 2 months before surgery
Trial: 19541299
Drug: Direct surgery
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct surgery without preoperative medical treatment
Trial: 12190134
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketorolac + 15 mg codeine phosphate
Trial: 12190134
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketorolac + codeine
Trial: 12190134
Drug: Codeine in
RxNorm normalized name: codeine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine in combination
Trial: 8882400
Drug: Multivitamin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplementation (0.8 mg of folic acid daily)
Trial: 8882400
Drug: Trace element
RxNorm normalized name: trace elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trace element supplement (placebo-like)
Trial: 1519784
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 25 micrograms.h‐1
Trial: 6831829
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 500 mg acetaminophen and 65 mg caffeine
Trial: 6831829
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg acetaminophen alone
Trial: 31418532
Drug: Brochure about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brochure about venous disease and compression therapy (case group)
Trial: 22502624
Drug: 1.0% copaiba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% copaiba essential oil preparation
Trial: 10348287
Drug: Intensive doxorubicin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive doxorubicin-containing chemotherapy and whole-lung irradiation
Trial: 10348287
Drug: Less aggressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less aggressive treatment with 2 or 3 drugs without whole-lung irradiation
Trial: 7586616
Drug: Naloxone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 20 mg
Trial: 7586616
Drug: Ovine corticotrophin‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine corticotrophin‐releasing hormone (oCRH) 1 microgram/kg
Trial: 7586616
Drug: Insulin 0.15U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.15U/kg
Trial: 1849413
Drug: AVE‐5 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE‐5 regimen (etoposide 60 mg/m2 IV on day 1 and 120 mg/m2 orally on days 2-5)
Trial: 1849413
Drug: AVE‐1 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE‐1 regimen (etoposide 300 mg/m2 IV on day 1)
Trial: 6418074
Drug: Chemo-endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-endocrine therapy (TAM+) with Mitomycin-C plus Tegafur and Tamoxifen 20 mg/day
Trial: 6418074
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (TAM-)